Mesbah-Oskui Lia, Horner Richard L
From the Departments of Medicine (L.M.-O.) and Physiology (R.L.H.), University of Toronto, Toronto, Ontario, Canada.
Anesthesiology. 2016 Nov;125(5):964-978. doi: 10.1097/ALN.0000000000001307.
Alterations in thalamic γ-aminobutyric acid-mediated signaling are thought to underlie the increased frontal α-β frequency electrocortical activity that signals anesthetic-induced loss of consciousness with γ-aminobutyric acid receptor type A (GABAAR)-targeting general anesthetics. The general anesthetic etomidate elicits phasic extrasynaptic GABAAR activation ("spillover" inhibition) at thalamocortical neurons in vitro. We hypothesize that this action of etomidate at the thalamus is sufficient to trigger an increase in frontal α-β frequency electrocortical activity and that this effect of etomidate is fully recapitulated by enhanced thalamic spillover inhibition in vivo.
We recorded electrocortical activity and sleep-wake behavior in freely behaving wild-type (n = 33) and extrasynaptic δ-subunit-containing GABAAR knockout mice (n = 9) during bilateral microperfusion of the thalamus with etomidate and/or other pharmacologic agents that influence GABAAR or T-type Ca channel activity.
Microperfusion of etomidate into the thalamus elicited an increase in α-β frequency electrocortical activity that occurred only during non-rapid-eye-movement (REM) sleep (11.0 ± 11.8% and 16.0 ± 14.2% greater 8 to 12- and 12 to 30-Hz power, respectively; mean ± SD; both P < 0.031) and was not affected by blockade of thalamic T-type Ca channels. Etomidate at the thalamus also increased spindle-like oscillations during non-REM sleep (4.5 ± 2.4 spindle per minute with etomidate vs. 3.2 ± 1.7 at baseline; P = 0.002). These effects of etomidate were fully recapitulated by enhanced thalamic extrasynaptic GABAAR-mediated spillover inhibition.
These findings identify how a prototypic GABAAR-targeting general anesthetic agent can elicit the characteristic brain wave pattern associated with anesthetic hypnosis when acting at the thalamus by promoting spillover inhibition and the necessity of a preexisting non-REM mode of activity in the thalamus to generate this effect.
丘脑γ-氨基丁酸介导的信号改变被认为是额叶α-β频率脑电活动增加的基础,这种脑电活动增加标志着使用靶向A型γ-氨基丁酸受体(GABAAR)的全身麻醉药后麻醉诱导的意识丧失。全身麻醉药依托咪酯在体外能诱发丘脑皮质神经元的阶段性突触外GABAAR激活(“溢出”抑制)。我们假设依托咪酯在丘脑的这一作用足以引发额叶α-β频率脑电活动增加,并且依托咪酯的这一效应在体内可通过增强丘脑溢出抑制而完全重现。
我们在自由活动的野生型小鼠(n = 33)和含有突触外δ亚基的GABAAR基因敲除小鼠(n = 9)双侧丘脑微量灌注依托咪酯和/或其他影响GABAAR或T型钙通道活性的药物期间,记录了它们的脑电活动和睡眠-觉醒行为。
向丘脑微量灌注依托咪酯可引起α-β频率脑电活动增加,这种增加仅在非快速眼动(REM)睡眠期间出现(8至12赫兹和12至30赫兹功率分别增加11.0±11.8%和16.0±14.2%;均值±标准差;P均<0.031),且不受丘脑T型钙通道阻断的影响。丘脑给予依托咪酯还可增加非REM睡眠期间的纺锤样振荡(依托咪酯给药时每分钟4.5±2.4个纺锤波,而基线时为3.2±1.7个;P = 0.002)。依托咪酯的这些效应可通过增强丘脑突触外GABAAR介导的溢出抑制而完全重现。
这些发现明确了一种靶向GABAAR的典型全身麻醉药在丘脑发挥作用时,如何通过促进溢出抑制引发与麻醉催眠相关的特征性脑电波模式,以及丘脑预先存在的非REM活动模式对产生这一效应的必要性。